Skip to content

To evaluate the action of Chandana Anjana and Tila Taila Padabhyanga in the management of Asthenopia.

A randomized open-label controlled clinical study to evaluate the efficacy of Chandana Anjana and Tila Taila Padabhyanga in the management of Asthenopia. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/068607
Enrollment
50
Registered
2024-06-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H53-H54- Visual disturbances and blindness

Interventions

None listed

Sponsors

Dr Akshat Vashisth
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects within the age group between 21 to 40 years irrespective of gender, caste, religion, and socio-economic status. 2. Subjects having at least two symptoms under diagnostic criteria. 3. Subjects having vision as 6/6 or 6/6 blur or N6 or N6 blur up to ± 1D. 4. Subjects willing to participate in the study with informed consent.

Exclusion criteria

Exclusion criteria: 1. History of any intraocular surgery. 2. Subjects having any ocular trauma. 3. Subjects having any uncontrolled systemic illness that can interfere with the course of disease and treatment. 4. Subjects diagnosed with infective diseases of the eye like Conjunctivitis, Uveitis, Scleritis, Keratitis, Stye, Trachoma, Endophthalmitis, Blepharitis, Retinitis and Dacryocystitis. 5. Subjects having refractive errors due to pathological conditions like Cataracts, Corneal opacity, Keratoconus, and Glaucoma. 6. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Significant improvement in the signs and symptoms of Asthenopia. Timepoint: Pre-treatment: 0th Day Post Treatment: 8th Day 1st Follow-up: 15th Day 2nd Follow-up: 30th Day

Secondary

MeasureTime frame
Generation of in-depth analyzed data on the different aspects of the disease. Generation of data on possible adverse drug reaction. Timepoint: Pre treatment: 0th Day Post Treatment: 8th Day 1st Follow up: 15th Day 2nd Follow up: 30th Day

Countries

India

Contacts

Public ContactDr Naveen B S

Sri Sri College of Ayurvedic Science and Research

navs009@gmail.com9844991405

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026